Akrivia Health enables organisations to securely work with the world’s largest and most in-depth dataset comprised of structured psychiatric data. Our platform contains over 440 billion datapoints representing interactions between clinicians and their patients.

Our team of domain specialists, including AI Scientists and Clinical Annotators, support clients in understanding psychiatry clinical data and how it can be used to develop precision psychiatry models.

We are developing a global community of individuals and organisations who are thought leaders in mental illness and dementias.


The Platform

The platform has been developed by the Akrivia Health team over the last five years. It enables registered Network users to securely conduct analysis using 2.7 million de-identified patient records from 11 NHS mental health hospitals.

The de-identified data has been structured using the Observational Medical Outcomes Partnership (OMOP) Common Data Model. All analytics and models generated are provided as statistical outputs and in an aggregated format, as per NHS standards ISB 1523.

Outputs from the data are not provided at a patient level. We are in the process of developing the ability to combine genetic and brain image data to support the creation of psychiatric precision modelling.

If you would like more information about the platform and become a registered Network user, please Contact Us.

Get in touch


As specialists in mental illness and dementias, Akrivia Health provides clients with support to help them better understand how data within psychiatry clinical records can help with their decision making.

The team is comprised of AI Scientists, Clinical Annotators and Clinical Researchers who are experienced in the use of psychiatry data and the development of psychiatry precision modelling.

We partner with the Department of Psychiatry, University of Oxford on specific projects where access to thought leadership in highly specialist areas is required.

If you are interested in how we can help you on one of your projects, please Contact Us.

Find out more

The Network

We are developing a global network of individuals and organisations who are interested in improving the lives of individuals by changing the trajectory of research. We share innovation, service improvements and research outcomes, benefiting the advancement of drug research and service development.

The network has access to updates on clinical research through regular events, webinars, forums and white papers.  In addition, registered users of the platform will be able to access training and information governance guidance.

If you would like to become part of the network, please Contact Us.

Find out more

Supporting the future of mental health

Akrivia Health supports the development of therapeutic and non-therapeutic improvements across multiple stages of the process. We have combined working with the world’s most in-depth psychiatric clinical database, with specialist AI Scientists and a global community of individuals to change the trajectory of research in mental illnesses and dementias. There are six key areas where we are able to help you

Early stage drug discovery

Clinical researchers can work with the de-identified data to identify unmet medical needs and the potential causes behind these conditions.

By working with the structured de-identified data, derived from clinical interventions and patient interactions, sub-optimal care could be identified.

The potential exists for researchers to identify unexpected benefits of drugs already in the market or unreported positive interactions between existing drugs.

Patient and Site Recruitment and Retention

Patient recruitment uses significant levels of resource during a clinical trial especially with small patient pools or with competing trials at a site.

It is estimated that 15-20% of sites which are activated for a trial never recruit a patient resulting in increased costs and risks to the trial. Once recruited 20% of patients drop out due to the burden of travel, outcome reporting, and taking the drugs is too great.

Our platform can help organisations to understand which sites may result in better patient recruitment and retention based upon the characteristics of the patients.

In addition, it can help identify the likelihood that there will be sufficient patients for screening due to exclusion criteria applied or whether the trial protocol needs to be changed.

Post Launch Evaluation and Pharma-covigilence

Following drug approval, regulatory bodies often require post launch studies to be conducted to assess the real-world impact of the drug. Currently this is conducted in a similar manner to phase I-III trials. In the future, it is expected that Phase IV trial evidence will be supported in silico by correctly structured data.

The collection, investigation of and reporting of adverse events consumes significant time and resource for drug companies. Access to large real-world evidence datasets will make detecting and investigating these events easier.

The combination of the Akriva Health platform, application of the OMOP Common Data Model and our AI Scientists provide the capability to identify the quality of data and the evidence that can be generated from the clinical records.

Market Access and Sales Tracking

The structuring of clinical records data using a common international standard means that the Akrivia Health platform can identify how and where drugs are being prescribed. This enables pharmaceutical companies to better understand the effectiveness of their marketing and the penetration of specific markets.

The data identifies which competing drugs are being used as an alternative, potentially within specific clinical scenarios, off label use and where potential compliance issues may exist. In addition, the data will be able to support Patient Access Schemes where the drug is considered to be too expensive by NICE in the UK.

Clinical Trial Revenue

Our global community can help to link healthcare organisations with Pharmaceutical and Biotechnology companies to help deliver their R&D Strategy, generate revenue and improve trial efficiencies.

It is estimated that a NHS hospital is paid £9,200 per patient that completes a clinical trial (source: KPMG 2019).  During 2018/19, NHS hospitals generated approximately £425m Gross Added Value per annum from participation in clinical trials across all care settings (source: KPMG 2019).

Service Evaluation and Quality Improvement audits

There is still limited opportunity to work with de-identified patient level data, that has been structured, to conduct strategic or operational reviews. Where it is available, organisations do not have the ability to extract key information due to data formats and a lack of coding standards, missing data and duplicate data.

Information Governance constraints often limit the capability to conduct analysis using a federated search. Our platform enables work to be conducted on models that are statistically valid across multiple organisations under a robust Information Governance model.

Unsure which service would best suit?

If you would like further information about the services that we offer, how they can help solve a specific problem or you would like to join our global community, please Contact Us.

Get in touch